| Literature DB >> 34808006 |
Diederik F M Hentenaar1, Yvonne C M De Waal2, Roy E Stewart3, Arie Jan Van Winkelhoff2, Henny J A Meijer1,2, Gerry M Raghoebar1.
Abstract
OBJECTIVES: To compare erythritol air polishing with implant surface cleansing using saline during the surgical treatment of peri-implantitis.Entities:
Keywords: dental implant; intervention study; peri-implantitis; randomized controlled trial; surgery
Mesh:
Substances:
Year: 2021 PMID: 34808006 PMCID: PMC9299917 DOI: 10.1111/clr.13881
Source DB: PubMed Journal: Clin Oral Implants Res ISSN: 0905-7161 Impact factor: 5.021
Descriptive statistics of clinical and radiographical outcomes test and control group
| Test | Control | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| Non‐surgical phase | Surgical follow‐up | Non‐surgical phase | Surgical follow‐up | |||||||||
| Outcomes | Tpre (27/54) | Tpost/T0 | T3 (25/52) | T6 (23/44) | T9 (23/49) | T12 (22/47) | Tpre (31/40) | Tpost/T0 | T3 (31/40) | T6 (30/39) | T9 (25/32) | T12 (23/30) | |
| Mean BoP (%) | Site level (SD) | 59.6 (31.7) | 52.2 (30.4) | 40.0 (28.0) | 33.4 (25.1) | 31.5 (24.3) | 34.0 (25.8) | 59.0 (26.7) | 58.3 (30.4) | 42.4 (26.0) | 41.0 (27.2) | 39.6 (27.2) | 44.4 (26.7) |
| Implant level (n) | 92.6 (54) | 90.7 (54) | 83.3 (52) | 79.5 (44) | 77.5 (49) | 80.1 (47) | 97.5 (40) | 95.0 (40) | 90.0 (40) | 87.2 (39) | 90.6 (32) | 86.6 (30) | |
| Mean SoP (%) | Site level (SD) | 15.7 (20.3) | 17.3 (22.2) | 6.7 (15.2) | 5.7 (16.1) | 7.8 (17.4) | 7.1 (15.4) | 16.7 (20.3) | 15.0 (21.6) | 8.0 (18.5) | 15.0 (27.0) | 10.9 (19.7) | 11.1 (19.8) |
| Implant level (n) | 51.9 (54) | 51.9 (54) | 19.2 (52) | 13.6 (44) | 18.4 (49) | 21.2 (47) | 65 (40) | 50.0 (40) | 27.5 (40) | 30.8 (39) | 28.1 (32) | 30.0 (30) | |
| Mean Plaq (%) | Site level (SD) | 21.9 (34.7) | 16.1 (34.6) | 18.0 (21.8) | 8.1 (12.2) | 19.1 (25.2) | 22.3 (37.3) | 18.3 (24.4) | 8.8 (16.0) | 20.5 (28.3) | 10.3 (14.6) | 11.1 (15.7) | 11.7 (14.6) |
| Implant level (n) | 37.0 (54) | 22.2 (54) | 57.7 (54) | 38.6 (44) | 57.1 (49) | 38.3 (47) | 47.5 (40) | 30.0 (40) | 55.0 (40) | 43.6 (39) | 46.9 (32) | 46.7 (30) | |
| PPD (mm) | Mean (SD) | 5.1 (1.4) | 4.9 (1.6) | 3.4 (1.1) | 3.5 (1.2) | 3.4 (0.9) | 3.3 (0.8) | 4.7 (1.0) | 4.6 (1.0) | 3.5 (1.2) | 3.7 (1.4) | 3.5 (1.2) | 3.5 (1.4) |
| MBL (mm) | Mean (SD) | 4.4 (1.9) | 4.3 (1.7) | 4.5 (1.7) | 4.3 (1.6) | NA | 4.5 (1.7) | 3.5 (1.6) | 3.7 (1.7) | 3.9 (1.8) | 3.7 (1.7) | NA | 3.8 (2.0) |
| Full‐mouth mean BoP (%) | Patient level (SD) | 10.6 (9.3) | 10.0 (7.3) | NA | NA | NA | 14.8 (8.2) | 13.0 (12.8) | 8.9 (6.9) | NA | NA | NA | 11.3 (9.2) |
| Full‐mouth mean SoP (%) | Patient level (SD) | 0.0 (0.0) | 0.0 (0.0) | NA | NA | NA | 0.7 (2.8) | 3.5 (0.2) | 0.0 (0.0) | NA | NA | NA | 0.0 (0.0) |
| Full‐mouth mean Plaq (%) | Patient level (SD) | 24.9 (20.9) | 19.9 (16.9) | NA | NA | NA | 15.1 (14.4) | 27.7 (13.0) | 22.1(14.5) | NA | NA | NA | 20.0 (10.8) |
| Full‐mouth mean PPD (mm) | Patient level (SD) | 2.1 (0.3) | 2.0 (0.6) | NA | NA | NA | 2.1 (0.23) | 2.0 (0.2) | 2.1 (0.3) | NA | NA | NA | 2.2 (0.2) |
Outcome at 3 months after non‐surgical treatment is baseline outcome for surgical treatment.
Measured on a 6‐point scale.
Measured at the mesial and distale site.
FIGURE 1Consort flow diagram
Baseline patient and implant characteristics.
| Test | Control | ||
|---|---|---|---|
| Patient characteristics | |||
| Total number of patients | 27 | 31 | |
| Age [years; mean (SD)] | 59.6 (13.6) | 59.3 (10.0) | |
| Gender; F (female)/M (male) | 12/15 | 13/18 | |
| Smoking; n subjects (%) | |||
|
| 5 (18.5) | 8 (25.8) | |
|
| 14 (51.9) | 20 (64.5) | |
|
| 8 (29.6) | 3 (9.7) | |
| History of periodontitis; n subjects (%) | |||
|
| 9 (33.3) | 12 (38.7) | |
|
| 18 (66.7) | 19 (61.3) | |
| Diabetes; n subjects (%) | |||
|
| 1 (3.7) | 1 (3.2) | |
|
| 26 (96.3) | 30 (96.8) | |
| Dental status, n patients (%) | |||
|
| 7 (25.9) | 6 (19.4) | |
|
| 20 (74.1) | 25 (80.6) | |
| Implant characteristics | |||
| Total number of implants | 80 | 83 | |
| Total number of implants presenting peri‐implantitis (range) | 54 (1–6) | 40 (1–3) | |
| Time in function [years; mean (SD)] | 8.9 (5.8) | 8.9 (6.1) | |
| Implant type; n implants (%) | |||
|
| 21 | 17 | |
|
| 22 | 14 | |
|
| 7 | 0 | |
|
| 0 | 3 | |
|
| 4 | 6 | |
| Implant surface | |||
|
| 22 | 17 | |
|
| 21 | 12 | |
|
| 11 | 11 | |
| Type of suprastructure; n implants (%) | |||
|
| 14 (25.9) | 28 (70.0) | |
|
| 18 (33.3) | 2 (5.0) | |
|
| 22 (40.7) | 10 (25.0) | |
| Screw‐ or cement‐retained restoration; n implants (%) | |||
|
| 38 (70.4) | 28 (70.0) | |
|
| 16 (29.6) | 12 (30.0) | |
| Implants placed in maxilla or mandible; n implants (%) | |||
|
| 36 (66.7) | 20 (50.0) | |
|
| 18 (33.3) | 20 (50.0) | |
| Implants placed anterior posterior; n implants (%) | |||
|
| 22 (40.7) | 16 (40.0) | |
|
| 32 (59.3) | 24 (60.0) | |
| Bone defect configuration and grade (according Schwarz et al., | |||
|
| |||
|
| buccal dehiscence | 2 (3.7%) | 4 (10.0%) |
|
| 2/3 wall defect | 9 (16.6%) | 12 (30.0%) |
|
| Circumferential | 3 (5.5%) | 2 (5.0%) |
| 2 | horizontal/supracrestal | 8 (14.8%) | 6 (15.0%) |
| 3a | horizontal/supracrestal +buccal dehiscence | 5 (9.3%) | 4 (10.0%) |
|
| horizontal/supracrestal +2/3 wall defect | 24 (44.4%) | 10 (25.0%) |
| 3c | horizontal/supracrestal +circumferential | 3 (5.5%) | 2 (5.0%) |
|
| |||
| A | slight 3–4 mm/<25% of the implant length | 11 (20.4%) | 15 (37.5%) |
| B | moderate 4–5 mm/25–50% of the implant length | 21 (38.9%) | 19 (47.5%) |
| C | advanced >6 mm/>50% of the implant length | 22 (40.7%) | 6 (15.0%) |
Generalized linear mixed model outcomes for mean difference in BoP, SoP, Plq, PPD, and MBL between test and control group at T12
| Crude analysis | Adjusted analysis | |||
|---|---|---|---|---|
| Outcome | β (95% CI) |
| β (95% CI) |
|
| Mean BoP | 0.034 (−0.009 to 0.077) | 0.120 | 0.037 (−0.016 to 0.089) | 0.170 |
| Mean SoP | 0.157 (−0.000 to 0.314) | 0.051 | 0.211 (0.017 to 0.406) |
|
| Mean Plq | −0.169 (−0.319 to −0.019) |
| −0.002 (−0.163 to 0.159) | 0.979 |
| Mean PPD | 0.083 (−0.018 to 0.184) | 0.108 | 0.052 (−0.075 to 0.178) | 0.423 |
| MBL | −0.019 (−0.063 to 0.025) | 0.405 | −0.030 (−0.098 to 0.037) | 0.377 |
Normal distributed data analyzed with linear model distribution.
Non‐normal distributed data analyzed with gamma distribution.
Adjusted for baseline value and time.
Adjusted for baseline value, time, smokin.g, history of periodontitis, mean periodontal full‐mouth plaque score at T12, mean marginal bone loss at T0, and implant surface.
Distribution of sites with BoP in implants with PPD < 5 mm, without suppuration and progressive bone loss > 0.5 mm
| Sites with BoP |
| Air polishing | Hand instrumentation |
|---|---|---|---|
| 0 out of 6 | 9 (9.6%) | 6 (25.0%) | 3 (18.8%) |
| 1 out of 6 | 9 (9.6%) | 7 (29.2%) | 2 (12.5%) |
| 2 out of 6 | 9 (9.6%) | 6 (25.0%) | 3 (18.8%) |
| 3 out of 6 | 6 (6.4%) | 2 (8.3%) | 4 (25.0%) |
| 4 out of 6 | 6 (6.4%) | 2 (8.3%) | 4 (25.0%) |
| 5 out of 6 | 1 (1.1%) | 1 (4.2%) | 0 (0.0) |
| 6 out of 6 | 0 (0.0%) | 0 (0.0%) | 0 (0.0) |
| 40/94 | 24/40 | 16/40 |
FIGURE 2Percentage of patients (%) with positive peri‐implant samples in test and control group for the presence of Aggregatibacter actinomycetemcomitans (Aa), Porphyromonas gingivalis (Pg), Prevotella intermedia (Pi), Tannerella forsythia (Tf), Fusobacterium nucleatum (Fn), Parvimonas micra (Pm), Treponema denticola (Td), and Filifactor alocis (Fa) before non‐surgical intervention (Tpre), 3 months after the non‐surgical intervention/before the surgical intervention (Tpost/ T0) and 12 months after the surgical intervention (T12)
FIGURE 3Percentage of patients (%) with positive periodontal samples in test and control group for the presence of Aggregatibacter actinomycetemcomitans (Aa), Porphyromonas gingivalis (Pg), Prevotella intermedia (Pi), Tannerella forsythia (Tf), Fusobacterium nucleatum (Fn), Parvimonas micra (Pm), Treponema denticola (Td), and Filifactor alocis (Fa) before non‐surgical intervention (Tpre), 3 months after the non‐surgical intervention/before the surgical intervention (Tpost/ T0), and 12 months after the surgical intervention (T12)